Status:

COMPLETED

Treatment of Actinic Keratosis With 5% KOH Solution

Lead Sponsor:

Infectopharm Arzneimittel GmbH

Collaborating Sponsors:

Gesellschaft für Therapieforschung mbH

Conditions:

Actinic Keratoses

Eligibility:

All Genders

30-80 years

Brief Summary

This is a prospective single-arm multicenter medical device study to investigate the clinical efficacy and safety of the treatment of actinic keratosis with a 5% potassium hydroxide solution. In tota...

Eligibility Criteria

Inclusion

  • Written informed consent
  • Age: 30 to 80 years
  • Adults with AK grade I (mild) or II (moderate)

Exclusion

  • Number of lesions requiring treatment \> 10
  • Lesion to be treated \> 20 mm (maximum diameter)
  • Lesions directly adjoining to the eyes, eyelids, nostrils, mouth or mucosal tissue,
  • Need for topical treatment of a cancerous area
  • Presence of a relapsing, persistent, indurated, thickened, painful, bleeding, ulcerated and/or rapidly growing lesion
  • Presence of a persistent or relapsing lesion despite appropriate treatment with AKOHDerm or another appropriate treatment
  • High risk of progression of AK according as assessed by a medical doctor
  • Pharmacological or physical local therapy of AK in the area foreseen for treatment dur-ing the last 12 weeks
  • Treatment with systemic corticosteroids during the last 2 weeks
  • Planned concomitant treatment of the same AK lesions during the study in addition to study treatment
  • Other skin diseases in the area of application which might interfere with clinical signs
  • Known predisposition for hypertrophic scarring / keloidosis
  • Primary or secondary immunodeficiency
  • Treatment with interferons, interferon inducers or immunomodulators during the last 4 weeks
  • Pregnancy and lactation
  • No reliable contraception in women of child-bearing potential
  • Other serious diseases which are according to the investigator in conflict with the par-ticipation
  • Obvious unreliability or lack of cooperation - known addiction to alcohol, medicinal products or drugs
  • Dependent relationship with sponsor or investigator
  • Participation in a clinical trial within the last 30 days
  • Previous participation in this study

Key Trial Info

Start Date :

October 17 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 25 2019

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT04024579

Start Date

October 17 2017

End Date

August 25 2019

Last Update

October 22 2019

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Dermatologisches Zentrum

Bonn, Germany, 53111

2

Hautzentrum Dülmen

Dülmen, Germany, 48249

3

Hautärztliche Praxis

Friedrichshafen, Germany, 88045

4

Hautzentrum Nymphenburg

München, Germany, 80639